GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study.
Journal
The Lancet. Rheumatology
ISSN: 2665-9913
Titre abrégé: Lancet Rheumatol
Pays: England
ID NLM: 101765308
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
entrez:
25
8
2020
pubmed:
25
8
2020
medline:
25
8
2020
Statut:
ppublish
Résumé
Mortality in patients with COVID-19 pneumonia and systemic hyperinflammation is high. We aimed to examine whether mavrilimumab, an anti-granulocyte-macrophage colony-stimulating factor receptor-α monoclonal antibody, added to standard management, improves clinical outcomes in patients with COVID-19 pneumonia and systemic hyperinflammation. This single-centre prospective cohort study included patients aged 18 years or older who were admitted to San Raffaele Hospital (Milan, Italy) with severe COVID-19 pneumonia, hypoxia, and systemic hyperinflammation. Patients received a single intravenous dose (6 mg/kg) of mavrilimumab added to standard care given by the hospital at the time. The control group consisted of contemporaneous patients with similar baseline characteristics who received standard care at the same hospital. The main outcome was time to clinical improvement (defined as improvement of two or more points on the seven-point ordinal scale of clinical status). Other outcomes included proportion of patients achieving clinical improvement, survival, mechanical ventilation-free survival, and time to fever resolution. Adverse events were monitored daily. Between March 17 and April 15, 2020, 13 non-mechanically ventilated patients (median age 57 years [IQR 52-58], 12 [92%] men) received mavrilimumab and 26 patients (median age 60 [IQR 53-67], 17 [65%] men) in the control group received standard care. During the 28-day follow-up, no patients in the mavrilimumab group died, and seven (27%) patients in the control group died (p=0·086). At day 28, all patients in the mavrilimumab group and 17 (65%) patients in the control group showed clinical improvement (p=0·030), with earlier improvement in the mavrilimumab than in the control group (mean time to improvement 8 days [IQR 5 to 11] Mavrilimumab treatment was associated with improved clinical outcomes compared with standard care in non-mechanically ventilated patients with severe COVID-19 pneumonia and systemic hyperinflammation. Treatment was well tolerated. Confirmation of efficacy requires controlled testing. IRCCS San Raffaele Scientific Institute.
Sections du résumé
BACKGROUND
BACKGROUND
Mortality in patients with COVID-19 pneumonia and systemic hyperinflammation is high. We aimed to examine whether mavrilimumab, an anti-granulocyte-macrophage colony-stimulating factor receptor-α monoclonal antibody, added to standard management, improves clinical outcomes in patients with COVID-19 pneumonia and systemic hyperinflammation.
METHODS
METHODS
This single-centre prospective cohort study included patients aged 18 years or older who were admitted to San Raffaele Hospital (Milan, Italy) with severe COVID-19 pneumonia, hypoxia, and systemic hyperinflammation. Patients received a single intravenous dose (6 mg/kg) of mavrilimumab added to standard care given by the hospital at the time. The control group consisted of contemporaneous patients with similar baseline characteristics who received standard care at the same hospital. The main outcome was time to clinical improvement (defined as improvement of two or more points on the seven-point ordinal scale of clinical status). Other outcomes included proportion of patients achieving clinical improvement, survival, mechanical ventilation-free survival, and time to fever resolution. Adverse events were monitored daily.
FINDINGS
RESULTS
Between March 17 and April 15, 2020, 13 non-mechanically ventilated patients (median age 57 years [IQR 52-58], 12 [92%] men) received mavrilimumab and 26 patients (median age 60 [IQR 53-67], 17 [65%] men) in the control group received standard care. During the 28-day follow-up, no patients in the mavrilimumab group died, and seven (27%) patients in the control group died (p=0·086). At day 28, all patients in the mavrilimumab group and 17 (65%) patients in the control group showed clinical improvement (p=0·030), with earlier improvement in the mavrilimumab than in the control group (mean time to improvement 8 days [IQR 5 to 11]
INTERPRETATION
CONCLUSIONS
Mavrilimumab treatment was associated with improved clinical outcomes compared with standard care in non-mechanically ventilated patients with severe COVID-19 pneumonia and systemic hyperinflammation. Treatment was well tolerated. Confirmation of efficacy requires controlled testing.
FUNDING
BACKGROUND
IRCCS San Raffaele Scientific Institute.
Identifiants
pubmed: 32835256
doi: 10.1016/S2665-9913(20)30170-3
pii: S2665-9913(20)30170-3
pmc: PMC7430344
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e465-e473Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL085453
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL118342
Pays : United States
Informations de copyright
© 2020 Elsevier Ltd. All rights reserved.
Références
JAMA. 2018 Feb 20;319(7):698-710
pubmed: 29466596
Arthritis Rheumatol. 2018 Jan;70(1):49-59
pubmed: 28941039
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
MAbs. 2016 Oct;8(7):1398-1406
pubmed: 27560702
Ann Rheum Dis. 2011 Sep;70(9):1542-9
pubmed: 21613310
Crit Care Resusc. 2020 Apr 01;22(2):91-94
pubmed: 32227819
J Clin Pharmacol. 2012 Aug;52(8):1150-61
pubmed: 21947370
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975
pubmed: 32350134
Trends Immunol. 2002 Aug;23(8):403-8
pubmed: 12133803
Annu Rev Physiol. 2002;64:775-802
pubmed: 11826288
Eur J Intern Med. 2020 Jun;76:43-49
pubmed: 32482597
Ther Adv Musculoskelet Dis. 2019 Oct 07;11:1759720X19878004
pubmed: 31636721
Lancet Rheumatol. 2020 Jun;2(6):e325-e331
pubmed: 32501454
Front Immunol. 2019 Sep 04;10:2055
pubmed: 31552022
Chest. 2007 Aug;132(2):410-7
pubmed: 17573487
J Thromb Haemost. 2020 Aug;18(8):2066-2067
pubmed: 32344457
Mediators Inflamm. 2015;2015:568543
pubmed: 25838639
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Blood. 2019 Dec 12;134(24):2119-2120
pubmed: 31830277
J Thromb Haemost. 2020 Jun;18(6):1324-1329
pubmed: 32306492
Arthritis Rheumatol. 2020 Feb;72(2):335-347
pubmed: 31400073
Lancet. 2020 Mar 14;395(10227):846-848
pubmed: 32151325
N Engl J Med. 2020 Jun 11;382(24):2372-2374
pubmed: 32302078
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Expert Opin Investig Drugs. 2019 Jul;28(7):573-581
pubmed: 31208237
N Engl J Med. 2003 Dec 25;349(26):2527-39
pubmed: 14695413
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143